Title: ANCHOR study 2-year results consistent with earlier data
Abstract: At month 24, 65.7% of patients treated with PDT, 90.0% of those treated with 0.3 mg ranibizumab, and 89.9% of those treated with 0.5 mg ranibizumab lost fewer than 15 letters compared with baseline. These results were very similar to the 12-month results.
Publication Year: 2007
Publication Date: 2007-03-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot